ETCTN 10558

Metastatic Neuroendocrine Tumors Therapeutic Follow-up

ETCTN 10558 phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors. We currently lack reliable blood biomarkers for the therapeutic follow-up of neuroendocrine tumors, making it challenging to monitor treatment efficacy and disease progression. This limitation hampers personalized treatment strategies and timely adjustments in patient care. In this study, we will evaluate, as an exploratory objective, whether hPG80 could be used to monitor treatment response in these patients.
 

The study will enroll 94 patients with metastatic neuroendocrine tumors. Blood samples will be taken before and during their treatment follow-up to evaluate plasma concentrations of hPG80.
 

Study in partnership with the National Cancer Institute (USA).

 

ETCTN 10558 is registered at ClinicalTrials.gov (NCT05724108)
 

Current Status: Enrolling